Home › Compound Library › Insulin Aspart (NovoLog)

Insulin Aspart (NovoLog)

Hormoneprescriptionsubcutaneous · inferred

Rapid-acting insulin analog with B28 proline→aspartic acid substitution that introduces charge repulsion, reducing hexamer stability and accelerating absorption. Onset ~15 min, peak 1-3h, duration 3-5h. Taken immediately before meals.

Projected serum levels — 10 units (≈ 0.35 mg), once daily

Insulin Aspart (NovoLog)
Insulin Aspart (NovoLog) modeled serum levels, 10 units (≈ 0.35 mg) once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 10 units (≈ 0.35 mg) once daily (subcutaneous).

Modeled steady state after ~1 days: peak ≈ 0.19 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Hormone
Route modeled
Subcutaneous
Model confidence
inferred
Half-life
1.3 h
Common dose
10 units (≈ 0.35 mg)
Suggested maximum
60 units/day
Reference dose range
5–60 units (single dose)
Suggested cadence
once daily

Documented interactions

  • moderate
    Insulin Glargine (Lantus) + Insulin Aspart (NovoLog) Stacked effects

    Insulin Aspart (NovoLog) and Insulin Glargine (Lantus) both push the igf1 receptor and insulin receptor in the same direction.

  • moderate
    Insulin Lispro (Humalog) + Insulin Aspart (NovoLog) Stacked effects

    Insulin Aspart (NovoLog) and Insulin Lispro (Humalog) both push the igf1 receptor and insulin receptor in the same direction.

  • moderate
    Insulin NPH (Humulin N) + Insulin Aspart (NovoLog) Stacked effects

    Insulin Aspart (NovoLog) and Insulin NPH (Humulin N) both push the igf1 receptor and insulin receptor in the same direction.

  • moderate
    Insulin Regular (Humulin R) + Insulin Aspart (NovoLog) Stacked effects

    Insulin Aspart (NovoLog) and Insulin Regular (Humulin R) both push the igf1 receptor and insulin receptor in the same direction.

Serum checks 4 modeled interaction pairings for insulin aspart (novolog) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial Home PD et al. · Diabetic Medicine, 2000 DOI

    Pivotal 6-month trial demonstrating insulin aspart improved postprandial glucose control and HbA1c vs regular human insulin in type 1 diabetes, with a trend toward fewer major hypoglycemic episodes, establishing aspart…

  2. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes Plank J et al. · Diabetologia, 2002 DOI

    Head-to-head crossover study finding insulin aspart and insulin lispro have nearly identical pharmacokinetic and pharmacodynamic profiles, with no clinically meaningful differences in postprandial glucose control or…

  3. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes Heller SR et al. · Diabetic Medicine, 2004 DOI

    Double-blind crossover trial showing insulin aspart produced fewer major nocturnal hypoglycemic episodes compared to regular human insulin, confirming safety advantages of rapid-acting analogs for intensive basal-bolus…

3 published studies referenced in the app, each with a plain-language summary.